Sec Form 4 Filing - Blobel Friedhelm @ SCICLONE PHARMACEUTICALS INC - 2017-10-13

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Blobel Friedhelm
2. Issuer Name and Ticker or Trading Symbol
SCICLONE PHARMACEUTICALS INC [ SCLN]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
President, CEO, Director
(Last) (First) (Middle)
950 TOWER LANE, SUITE 900
3. Date of Earliest Transaction (MM/DD/YY)
10/13/2017
(Street)
FOSTER CITY, CA94404
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/13/2017 M 95,000 A 237,299 ( 2 ) D
Common Stock 10/13/2017 A 150,000 ( 3 ) A $ 0 387,299 D
Common Stock 10/13/2017 D 387,299 D $ 11.18 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy) ( 4 ) $ 5.13 10/13/2017 D 142,610 ( 5 ) 05/12/2021 Common Stock 142,610 $ 6.05 ( 6 ) 0 D
Non-Qualified Stock Option (right to buy) ( 4 ) $ 6.22 10/13/2017 D 200,000 ( 7 ) 03/15/2022 Common Stock 200,000 $ 4.96 ( 6 ) 0 D
Non-Qualified Stock Option (right to buy) ( 4 ) $ 4.53 10/13/2017 D 200,000 ( 8 ) 04/04/2023 Common Stock 200,000 $ 6.65 ( 6 ) 0 D
Non-Qualified Stock Option (right to buy) ( 4 ) $ 4.52 10/13/2017 D 200,000 ( 9 ) 03/14/2024 Common Stock 200,000 $ 6.66 ( 6 ) 0 D
Incentive Stock Option (right to buy) ( 4 ) $ 8.83 10/13/2017 D 42,725 ( 10 ) 03/16/2025 Common Stock 42,725 $ 2.35 ( 6 ) 0 D
Restricted Stock Unit ( 4 ) ( 1 ) 10/13/2017 M 10,000 ( 11 ) ( 11 ) Common Stock 10,000 ( 1 ) 0 D
Non-Qualified Stock Option (right to buy) ( 4 ) $ 8.83 10/13/2017 D 97,275 ( 10 ) 03/16/2025 Common Stock 97,275 $ 2.35 ( 6 ) 0 D
Restricted Stock Unit ( 4 ) ( 1 ) 10/13/2017 M 50,000 ( 11 ) ( 11 ) Common Stock 50,000 ( 1 ) 0 D
Incentive Stock Option (right to buy) ( 12 ) $ 9.12 10/13/2017 D 11,243 ( 13 ) 03/15/2026 Common Stock 11,243 $ 2.06 ( 6 ) 0 D
Non-Qualified Stock Option (right to buy) ( 12 ) $ 9.12 10/13/2017 D 128,757 ( 13 ) 03/15/2026 Common Stock 128,757 $ 2.06 ( 6 ) 0 D
Restricted Stock Unit ( 12 ) ( 1 ) 10/13/2017 M 15,000 ( 11 ) ( 11 ) Common Stock 15,000 ( 1 ) 0 D
Incentive Stock Option (right to buy) ( 12 ) $ 9.65 10/13/2017 D 10,843 ( 14 ) 03/08/2027 Common Stock 10,843 $ 1.53 ( 6 ) 0 D
Non-Qualified Stock Option (right to buy) ( 12 ) $ 9.65 10/13/2017 D 129,157 ( 14 ) 03/08/2027 Common Stock 129,157 $ 1.53 ( 6 ) 0 D
Restricted Stock Unit ( 12 ) ( 1 ) 10/13/2017 M 20,000 ( 11 ) ( 11 ) Common Stock 20,000 ( 1 ) 0 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Blobel Friedhelm
950 TOWER LANE, SUITE 900
FOSTER CITY, CA94404
X President, CEO, Director
Signatures
/s/ Friedhelm Blobel, Ph.D. 10/16/2017
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Each restricted stock unit represented a contingent right to receive one share of SCLN common stock upon settlement.
( 2 )Includes 216 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on October 6, 2017 and 746 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on August 31, 2017.
( 3 )Shares of SCLN common stock received in settlement of performance rights not constituting derivative securities.
( 4 )Granted under Issuer's 2005 Equity Incentive Plan.
( 5 )Under its terms the option became exercisable in installments with 25% vesting on April 5, 2012 and 2.0833% vesting each month thereafter until it became vested in full on April 5, 2015.
( 6 )The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
( 7 )Under its terms the option became exercisable in installments with 25% vesting on March 15, 2013 and 2.0833% vesting each month thereafter until it became vested in full on March 15, 2016.
( 8 )Under its terms the option became exercisable in installments with 25% vesting on April 4, 2014 and 2.0833% vesting each month thereafter until it became vested in full on April 4, 2017.
( 9 )Under its terms the option became exercisable in installments with 25% vesting on March 14, 2015 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
( 10 )Under its terms the option became exercisable in installments with 25% vesting on March 16, 2016 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
( 11 )Restricted stock units became fully vested and entitled to settlement immediately prior to the Merger and terminated upon settlement in shares of SCLN common stock.
( 12 )Granted under Issuer's 2015 Equity Incentive Plan.
( 13 )Under its terms the option became exercisable in installments with 25% vesting on March 15, 2017 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
( 14 )Under its terms the option became exercisable in installments with 25% to vest on March 8, 2018 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.